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New WHO Guide to Prevent and Control
Cervical Cancer
Ale zehra, Clinical Pharmacist

Cervical cancer is one of the world’s
Comprehensive
deadliest but most easily preventable forms
Cervical Cancer Control
of cancer for women, responsible for more
A guide to essential practice
than 270000 deaths annually, 85% of which
Second edition
occur in developing countries. An estimated
one million-plus women worldwide are
currently living with cervical cancer. On 3rd
December 2014, the new “Comprehensive
cervical cancer control”(also known as pink
book) was launched by WHO. The new WHO
guide provides a comprehensive cervical
cancer control and prevention approach for
governments and healthcare providers.
The main elements of the new guide are:
l
Vaccinate 9 to 13-year-old girls with two doses of Human
papillomavirus (HPV) vaccine to prevent infection with the HPV.
The reduced, 2-dose schedule has been shown to be as effective as the
current 3-dose schedule.
l
Use HPV tests to screen women for cervical cancer prevention. With
HPV testing, the frequency of screening will decrease. Once a woman
has been screened negative, she should not be rescreened for at least 5
years, but should be rescreened within 10.
The new guide line identifies key opportunities and ages throughout a woman’s
life when cervical control and prevention can be put into action, especially for:
l
Primary prevention: human papillomavirus (HPV) vaccination
targets girls aged 9 to 13 years, aiming to reach them before they
become sexually active.
l
Secondary prevention: access to technology for women over 30 years
of age, such as VIA (visual inspection of the cervix with acetic acid)
or HPV testing for screening, followed by treatment of detected
precancerous lesions, which may develop into cervical cancer.
l
Tertiary prevention: access to cancer treatment and management for
women of any age, including surgery, chemotherapy and radiotherapy.
l
When curative treatment is no longer an option, access to palliative
care is crucial.
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Analgesic use in Adult Patients with Advanced Chronic Liver Disease
or Cirrhosis
Dr. Hafsah M. Ashfaq, Pharmacist.

Patients with liver disease may develop acute or chronic pain from a variety of causes. In addition to causes common
in the otherwise healthy population, those with advanced liver disease may have ascites (leading to abdominal and
lower back pain) and gynecomastia (leading to mastalgia).
Management of pain in patients with liver disease raises special concerns. The choice of appropriate analgesic agents
requires a thorough understanding of their pharmacokinetic and side effect profiles.
Altered Response and Pharmacokinetics

Management Suggestions

Non-opioid analgesics
Acetaminophen
(Paracetamol)

Glutathione tissues are reduced in
individuals with cirrhosis, thereby
lowering the dose threshold of
acetaminophen that can be safely
administered each day.

l

l

Acetaminophen is generally well 		
tolerated in patients with CLD or 		
cirrhosis, provided the total daily
dose is limited to no more than 2 g/
day (4 tablets of 500mg/day)
Also note that Paracetamol is
available in combination of other
pain killers and muscle relaxants
also so same caution should be
exercised in these products. E.g.
Nuberol, Nuberol Forte, Codogesic
etc.

Non-selective NSAIDs

NSAIDs can decrease GFR and impair NSAIDs and aspirin should be avoided
renal function in patients with advanced in patients with advanced CLD or
CLD or cirrhosis.
cirrhosis.

Selective COX-2
inhibitors

Excess cardiovascular events have been If used, Celecoxib product information
observed with this class of medications suggests a 50% dose reduction for
when used by patients without cirrhosis. Child-Pugh class B cirrhosis.

Opioid analgesics (see NOTE)*
Fentanyl

Morphine

Tramadol

Parent drug can accumulate after
repeated dosing or when administered as
a continuous infusion due to tissue and
protein binding.

Generally a good choice for patients
with CLD or cirrhosis when opiate
treatment indicated.
With repeated dosing, reduce dose and
frequency by approx. 25-50%

Half-life can be increased by twofold.
Accumulation of metabolites with
complex effects can occur in patients
with cirrhosis and renal failure.
Unpredictable onset, variable analgesic
efficacy, and risk of accumulation in
patients with cirrhosis.

Reduce dose and frequency by approx.
50 % Avoid in patients with cirrhosis
and renal failure as much as possible
Avoid use in patients with
decompensated cirrhosis.
A reduced dose of 25 mg every eight
hours may be considered.
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Altered Response and Pharmacokinetics
Meperidine (Pethidine), Unpredictable analgesic efficacy and
Codeine
increased risk of toxicity in CLD or
cirrhosis patients.

Management Suggestions
Meperidine/Pethidine and Codeine
should be avoided in such patients

Adjunctive agents for neuropathic pain

Gabapentin

Not hepatically metabolized, dependent
upon renal clearance.
Sedation and dizziness may limit
usefulness in patients with advanced
CLD or cirrhosis.

Initiate treatment at 300 mg orally
per day and gradually titrate dose.
Maintenance dose is dependent upon
renal function.

Pregabalin

Not hepatically metabolized, dependent
upon renal clearance.
Sedation and dizziness may limit
usefulness in patients with advanced
CLD or cirrhosis.

Initiate treatment at 50 mg orally twice
per day and gradually titrate dose.
Maintenance dose is dependent upon
renal function.

Nortriptyline

Accumulation of metabolites in
hepatic impairment is less likely with
Nortriptyline.

Initiate treatment at 10 mg orally HS
and gradually titrate dose

Carbamazepine

Carbamazepine has been associated
with hepatotoxicity and serious allergic
reactions

Carbamazepine should be avoided

* NOTE: All opioids can worsen or precipitate Hepatic Encephalopathy and should be used cautiously or
avoided in patients with portal hypertension and preexisting Hepatic Encephalopathy

The Novel Treatment of Clostridium Difficile Associated Diarrhea
(CDAD)
Harris Ahmed, Trainee Pharmacist

The emergence of Clostridium difficile associated disease (CDAD) is one of the important problems associated with widespread antibiotic use. Alteration of natural gut flora due to broad-spectrum antibiotic use leads
to gut colonization by the aerobic, gram-positive, spore producing bacillus Clostridium difficile. C. difficile
produces potent exotoxins that cause inflammatory, secretory diarrhea and colitis; in severe cases it may even
lead to death. Any antibiotic may predispose to colonization by C. difficile, including Metronidazole and Vancomycin, the two first line agents used to treat CDAD. Thus hospitals must have a solid antimicrobial stewardship program that ensures rational antibiotic use to minimize the growth, emergence and increasing virulence
of C. difficile.
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Treatment of Clostridium Difficile
Antibiotic Therapy
Initial Episode:
First relapse

Second relapse

Subsequent relapse

Studies of Rifaximin:

Oral Metronidazole: 500 mg Q8H or 250 mg Q6H for 10 to 14 days
Oral Vancomycin: 125 mg orally Q6H for 10 to 14 days
Rectal Vancomycin: 500mg in 100ml NS Q6h + Metronidazole IV
Repeat treatment as in initial episode above.
Alternative: Fidaxomicin1 200 mg orally q12h for 10 days
Tapering and pulsed oral Vancomycin :
125 mg PO Q6H for 7 to 14 days
125 mg PO Q12H for 7 days
125 mg PO QD for 7 days
125 mg PO every other day for 7
days
125 mg PO QD every 3 days for 14 days.
Alternative: Fidaxomicin1 200 mg PO Q12H for 10 days
Fidaxomicin1 200 mg orally twice daily for 10 days if not used
previously
Fecal bacteriotherapy (fecal microbiota transplant)
Consider anion binding resins with Vancomycin
Some studies have shown that sequential therapy with Vancomycin
followed by Rifaximin may be effective for recurrent Clostridium
difficile. However, exposure to rifamycins prior to development of
CDI is a risk factor for rifampin-resistant C. difficile infection.

Non- Antibiotic Therapy

1

Fecal Microbiota Transplant
(FMT):

Single to multiple infusions of bacterial fecal flora originating from a
healthy donor via a colonoscopy, an enema or a nasogastric tube

Anion Binding Resins

It’s used as an adjuvant 2-3 hours apart from Vancomycin. It
neutralizes the exotoxins produced by C. difficile.
Example: Colestyramine, Colestipol1, Tolevamer1

Intravenous Immunoglobulin
(IVIG)

It contains a C. difficile antitoxin and has been used in some patients
with recurring CDI. Its effectiveness has not been properly elucidated

Probiotics

Effective in mild CDI

Not yet registered in Pakistan

Proton-Pump Inhibitors (PPIs) – Are we over using them?
Dr. Salwa Ahsan - Manager Inpatient Pharmacy

Proton-pump inhibitors (PPIs) remain the major evidence-based therapy for upper GI disorders, including
GERD, dyspepsia, and peptic ulcer disease. The strong evidence supporting PPI efficacy and a favorable
safety profile may have contributed to significant over-prescription, exposing patients to an increasing number
of potential risks.
l
In ambulatory care setting, the overutilization of PPIs is often a result of failure to re-assess the need
		 for continuation of therapy, or insufficient use of on-demand and step-down therapy.
l
PPI overutilization in the inpatient setting is often a result of inappropriate stress ulcer prophylaxis
		 (SUP) in non-intensive care unit patients, and failure to discontinue SUP prior to hospital discharge.
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Indication in Inpatient:
From an inpatient perspective, appropriate initiation of PPI treatment would be limited to primary conditions
requiring directed therapy such as undifferentiated upper GI bleed, duodenal or gastric ulcer, or erosive
esophagitis] or a select population of intensive care unit (ICU) patients requiring prophylaxis.
Stress Ulcer Prophylaxis (SUP):
Prophylaxis is generally recommended in patients who are critically ill with risk factors for physiological
stress-related bleeding, including respiratory failure, coagulopathy, sepsis, severe hypotension, acute renal
failure, history of GI ulcer or a GI bleed within 1 year of admission, hepatic failure, major trauma, burns,
spinal cord injury, organ transplantation, Glasgow Coma Score up to 10, surgery, high-dose corticosteroid
therapy, renal failure, or ICU stay of at least 6 days.
Patients receiving SUP should be assessed daily and when their risk factors resolve and clinical condition
improves, discontinuation of SUP should be considered. Enteral nutrition may have prophylactic benefit in
patients who are critically ill by optimizing splanchnic blood flow, enhancing secretion of cytoprotective
prostaglandins, buffering acid, or other mechanisms – thus can be considered.
Discontinuation of SUP should also be considered when patients are transferred out from the ICU. Outside of
the ICU, the only indications for initiation of PPI in the inpatient setting are GI diagnoses or conditions that
warrant treatment.
Potential consequences of prolonged PPI therapy:
This includes hypergastrinemia, enterochromaffin-like cell hyperplasia, and parietal cell hypertrophy, leading
to rebound acid hypersecretion.
PPIs have been linked via retrospective studies to increased risk of enteric infections including Clostridium
difficile-associated diarrhea, community-acquired pneumonia, bone fracture, nutritional deficiencies (Vitamin
B12 (cobalamin) deficiency), and possible interference with metabolism of antiplatelet agents.
Reducing inappropriate prescribing of PPIs in the inpatient and outpatient settings can minimize potential for
adverse events, and foster controllable cost expenditure.
Duration of therapy:
The Food and Drug Administration (FDA) advises that no more than three 14-day treatment courses should be
used in one year in order to avoid side effects induced by PPI.
Available PPIs in AKUH Formulary with Price (per unit):
Drugs

IV

PO1

Indication in
Pediatrics*
1 year and older

Dosing

Comments

Once
daily
Once
daily
Once
daily

Daily dosages of > 80 mg
should be administered in
divided doses
Twice daily for pathological
Hypersecretory Conditions
Including Zollinger-Ellison
Syndrome

Omeprazole** 40 mg
289/-

20 mg, 13.57/40 mg, 18.5/-

Esomeprazole

-

20 mg, 11.5/40 mg, 20/-

1 year and older

-

40 mg, 62/-

5 years and older

Pantoprazole

* As per manufacturer
**compounded oral solution is also available
administer 30 minutes before meal on empty stomach. Granules of capsule must not be crushed- use oral solution if to
be given through NG tube.

1
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Characteristic

Omeprazole

Pantoprazole

Esomeprazole

Bioavailability (%)

30 to 40

77

90% (repeated once-daily
dosing) and 64% (single dose)

Time to peak plasma
concentration (hours)

0.5 to 3.5

1.1 to 3.1

1.5

Plasma elimination half-life
(hours)

0.5 to 1.0

1.0 to 1.9

1 to 1.5

Protein binding (%)

95

98

97

Urinary excretion of oral
dose (%)

77

71 to 80

1

Duration of action (hours)

24

24

24

IV to PO Switch Guidelines
Drug & Poison Information Team

Introduction
IV to oral switch is the prompt conversion of IV antibiotic therapy to oral. Patients may be considered candidates for switching from IV to oral therapy once the patient has shown clinical improvement and is medically
stable.
Rationale
The majority of patients with a severe infection who are adequately absorbing oral medication and initially
require IV therapy can be safely switched to oral therapy within 48 hours. There are a number of advantages
to support the prompt switch from IV to oral therapy these are as follows 1,2,3:
l
l
l
l
l
l

Reduction in the likelihood of hospital acquired bacteraemia and infected/phlebitic IV lines.
Saves both medical and nursing time
Reduces discomfort for patients and enables improved mobility and the possibility of earlier hospital discharge.
Potential to significantly reduce treatment costs.
Patient is more likely to receive antibiotics at the correct time.
Potential reduction in the risk of adverse effects; errors in preparation are significantly higher with
parenteral drugs, compared to oral formulation.

Considerations for the early switch to oral therapy: COMS (review at 24-48 hours)
C Clinical improvement observed
O Oral route is not compromised (vomiting, malabsorptive disorder, swallowing problems, unconscious,
severe diarrhea)
NB: if NG/PEG feeding then please consult your pharmacist for appropriate dosage form
M Markers showing a trend towards normal: Patient should be afebrile for the last 24 hours (Temp >360
C and <380 C) and DO NOT have more than one of the following, heart rate >90/min, resp rate >20/min, BP
unstable, WBC<4 or >12 (WBC/neutrophils should show a trend towards normal); absence of such should not
impede the switch if all other criteria are met and not neutropenic.
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S Specific indication/deep-seated infection (Prior to switch refer to table 1)
High risk/deep-seated infections
Certain infections may appear to respond promptly to intravenous therapy, but warrant prolonged IV therapy.
This is to ensure that adequate drug levels are attained at the site of infection and to optimize the response and
prevent relapse.
Discuss with Microbiology before switching patients with a high risk/deep seated infection to oral therapy.
Deep seated infections that may require an initial
2 weeks of IV therapy

High risk infections requiring prolonged IV
therapy

l

Liver abscess

l

Staphylococcus aureus bacteraemia

l

Osteomyelitis, Septic arthritis

l

Severe necrotizing soft tissue infections

(N.B. high-dose oral Clindamycin may be
appropriate once patient is stable)

l

Severe infections during chemotherapy
related neutropenia

l

Empyema

l

Infected implants/prosthesis

l

Cavitating pneumonia

l

Meningitis/encephalitis

l

Intracranial abscesses

l

Mediastinitis

l

Endocarditis

l

Exacerbation of cystic fibrosis/bronchiectasis

l

Inadequately drained abscesses or empyema

Proud to Report
Best Oral Presentation at 7th Medication Safety Conference, Abu Dhabi, UAE.

The 7th Medication Safety Conference 2014, Abu Dhabi, UAE: the best oral presentation award won by Ms. Farhat Zaheer (specialist, Compounding, IV admixture & Chemo section) and
her team .Title of the project was “Strategies to enhance and reduce turnaround time of sterile and non-sterile compounding preparations for ambulatory care patients” Approximately
140 entries from 50 different countries were presented, while AKUH’s entry presented by Ms. Farhat Zaheer was declared the winner. This was a quality improvement project related to
process re-designing and innovative strategies that bring efficiency and reduce turn around timings of sterile/non-sterile compounded medications for ambulatory care patients at AKUH.
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25th September, World Pharmacist Day-Celebration

Department of Pharmacy Services at the AKUH celebrated World Pharmacist Day( cake cutting + symposium+ stall) in collaboration with the
Society of Hospital Pharmacists of Pakistan and Hospital Pharmacy Section of FIP-International Pharmaceutical Federation based in Hague, The
Netherlands. Such platform identifies the contributions of pharmacist along with other health care professionals in developing a better health and
ultimately bringing better quality to life.

The Aga Khan University Hospital, Karachi

